The cost of research and development for a single new treatment that reaches the market is enormous and rising, with estimates ranging from $1 billion to $2 billion. Because of the high cost of development and the need to quickly access multiple technologies, it is more cost-effective (clinically and financially) to optimize existing drugs for potency, selectivity, drug metabolism, and dosing convenience before they reach the market. This has resulted in the development of orally disintegrating tablets. Orally disintegrating tablets are patient-oriented pharmaceutical preparations which aim to enhance the safety and efficacy of the drug molecule by formulating a dosage form which disintegrates or dissolves in a few seconds after placement in the mouth. This dosage form has gained popularity among the general public because it is easily administered to geriatrics patients, pediatric patients, patients with poor physiological abilities (e.g., patients suffering from mental disorders), and patients with physical abilities (e.g., patients suffering from dysphagia), traveling patients that may not have ready access to water, and to patients that are in a situation where swallowing conventional solid oral-dosage forms presents difficulties. These tablets can be prepared in many ways like direct compression, freeze drying, sublimation, molding, and spray drying by using single or combinations of superdisintegrants or subliming agents.
Download full-text PDF |
Source |
---|
Ther Deliv
January 2025
Global Specialty Excellence, Viatris Inc, New York, USA.
Orodispersible film (ODF) is one of the novel formulations that disintegrate rapidly in the mouth without the requisite for water compared to other conventional oral solid dosage formulations. This delivery system serves as a convenient mode of administration, especially in patients who have dysphagia and fluid restriction, being beneficial to pediatric, geriatric, and bedridden patients. A novel sildenafil ODF containing sildenafil citrate is formulated to be used in patients with erectile dysfunction (ED).
View Article and Find Full Text PDFJ Headache Pain
January 2025
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Background: Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAINER, a prospective, multicentric study, aimed to evaluate rimegepant effectiveness and tolerability in the real-world setting.
View Article and Find Full Text PDFMed Lett Drugs Ther
December 2024
Int J Pharm
December 2024
Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15-222 Bialystok, Poland. Electronic address:
In this study, lyophilizates with the second-class antipsychotic agent lurasidone hydrochloride were developed as orodispersible platforms to improve patients' adherence. The primary aim was to evaluate the effect of the amino acid additive (L-arginine, L-lysine, L-histidine) and the freeze-drying stage on the pharmaceutical performance of the designed formulations. The composition was initially optimized using an experimental design approach.
View Article and Find Full Text PDFMol Pharm
January 2025
Department of Health Technology, Technical University of Denmark, Oersteds Plads 344B, 2800 Kgs. Lyngby, Denmark.
Buccal delivery offers a promising alternative to e.g., oral or parenteral drug administrations by leveraging the mucosal membranes of the mouth to enhance drug absorption and enhance patient compliance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!